NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Pharmacogenetics and Genomics
S SuvichapanichKatsushi Tokunaga

Abstract

NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients with NAT2 genotypes of *6A/*6A, *6A/*7B and *7B/*7B are referred to in this group. We aim to prove an association of the NAT2 ultra-slow acetylators with the risk of ATDILI. Systematic review and meta-analysis were performed based on each NAT2 genotype and risk of ATDILI cases and also new classification of the ultra-slow acetylators up to 31 October 2016. Meta-analysis of 18 studies with 822 ATDILI cases and 4630 controls was carried out in the RevMan software, version 5.3 with fixed-effect (low heterogeneity) and random effect (moderate to high heterogeneity) methods. The strong associations between each NAT2 slow acetylator genotypes and ATDILI were confirmed in meta-analysis except for NAT2*5B/*5B [odds ratio (OR): 1.69; 95% confidence interval (CI): 0.96-2.95; P=0.0679]. The NAT2 ultra-slow acetylators contribute to higher risk of ATDILI (OR: 3.60; 95% CI: 2.30-5.63; P=1.76E-08) than all NAT2 slow acetylators (OR: 2.80; 95% CI: 2.20-3.57; P=5.73E-18) as well as fast acetylators. Additional in-vitro stud...Continue Reading

References

Jul 1, 1975·Clinical Pharmacology and Therapeutics·J R MitchellH R Keiser
Mar 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T YamamotoC Hirayama
Dec 1, 1982·Journal of Toxicology and Environmental Health·M D Scales, J A Timbrell
Jun 1, 1995·Postgraduate Medical Journal·J SinghR K Tandon
Mar 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yi-Shin HuangShou-Dong Lee
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jun 14, 2006·European Journal of Clinical Pharmacology·Nicolas VuilleumierDenis Hochstrasser
Feb 29, 2008·BMC Genetics·Audrey SabbaghEstella S Poloni
Jun 17, 2010·Calcified Tissue International·Emily R DodwellBrian Snyder
Jan 26, 2011·Journal of Gastroenterology and Hepatology·Purabi Deka BosePremashis Kar
Oct 21, 2011·Memórias do Instituto Oswaldo Cruz·Raquel Lima de Figueiredo TeixeiraAdalberto Rezende Santos
Jan 31, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·V Leiro-FernandezA Fernández-Villar
Mar 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P-Y WangB-F Jiang
Apr 18, 2012·Clinical and Experimental Pharmacology & Physiology·Hui-Ru AnYan Liang
Apr 18, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A KumarP K Dewan
Feb 12, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N P C SantosM H Hutz
Mar 7, 2014·Journal of the Chinese Medical Association : JCMA·Yi-Shin Huang
Apr 20, 2016·The Pharmacogenomics Journal·N Ben FredjK Aouam
Jun 25, 2016·Human Genome Variation·Taisei MushirodaKatsushi Tokunaga
Oct 12, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S WattanapokayakitK Tokunaga

❮ Previous
Next ❯

Citations

Oct 24, 2020·Expert Opinion on Drug Metabolism & Toxicology·David W Hein, Lori M Millner
Nov 24, 2020·Expert Opinion on Drug Metabolism & Toxicology·Camilla StephensRaúl J Andrade
Nov 3, 2020·Clinical Pharmacology and Therapeutics·Paola NicolettiGuruprasad P Aithal
Jan 10, 2021·Human Genome Variation·Nuanjun WichukchindaSurakameth Mahasirimongkol
Dec 16, 2019·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Mengyuan LyuBinwu Ying
Aug 11, 2021·American Journal of Respiratory and Critical Care Medicine·Renu VermaJason R Andrews

❮ Previous
Next ❯

Methods Mentioned

BETA
chemical modification
acetylation
acetylators
genotyping
Protein Assay
ELISA
of

Software Mentioned

R Foundation for Statistical Computing
Review Manager ( RevMan )
ATDILI
SNPAlyze
SHEsis
Scopus
GraphPad Prism
R
Unphase
GraphPad

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
S WattanapokayakitKatsushi Tokunaga
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
N TangG Zhou
© 2022 Meta ULC. All rights reserved